Researchers have found that by genetically editing bone marrow stem cells of pigtail...
- AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
- TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
- ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
- CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
- Vaccine development: the need for speed
Gene-edited stem cells reduce HIV risk in non-human primates
Researchers have found that by genetically editing bone marrow stem cells of pigtail macaques infected with simian/human immunodeficiency virus (SHIV), the size of dormant ‘viral reservoirs’ can be reduced, decreasing the risk of the disease reactivating.
Gene therapy for beta-thalassaemia could eliminate need for transfusions
A gene therapy trial for transfusion-dependent thalassaemia, an inherited blood disorder, gave positive results in an interim analysis, with the majority of patients being transfusion-free following treatment.
Low-cost anti-hookworm treatment found to be effective
A study co-authored by Yale researchers and non-profit company InnovationsCZ has reported the efficacy of a low-cost deworming drug in farm workers infected with hookworms.
AACR 2018: revisiting murine models to develop drug combos for KRAS-driven cancers
Treatment of KRAS-driven cancers is among one of the highest unmet needs in the oncology space.
AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
This year’s AACR meeting provided exciting preliminary data for additional therapeutic biomarkers in SCLC
TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
The future of TaiwanJ Pharmaceuticals’ JKB-121 as a NASH treatment is in jeopardy after it failed to demonstrate efficacy in a Phase II placebo-controlled trial, presented at the 2018 International Liver Congress (ILC) in Paris, France.
ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
Phase II efficacy data for NGM Biopharmaceuticals’ developmental non-alcoholic steatohepatitis (NASH) drug, NGM282, was presented at the 2018 International Liver Congress (ILC) in Paris, France.
Potential drug target for anti-obesity treatment discovered
Researchers have determined the molecular structure of the neuropeptide Y1 receptor (Y1R), a protein of central importance in food intake, which paves the way for new treatments for diseases such as obesity, type 2 diabetes and metabolic syndrome.
Novartis to invest $100m in antimalarials over the next five years
Novartis has announced plans to invest more than $100m into the research and development of next-generation antimalarial treatments over the next five years.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.